A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack
More Data To Be Reported At CTAD In November
Executive Summary
Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.
You may also be interested in...
Five Clinical Trial Hits Of 2022
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.
Reunited At Last At J.P. Morgan; Will The Sparks Still Fly?
The annual J.P. Morgan Healthcare conference will return to San Francisco on 9 January after being held virtually for two years.
CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure
Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody.